Premature ventricular contractions

Articolo redatto e revisionato del Dott. Luca Moretti

Premature ventricular contractions are premature activations arising in the ventricular myocardium or in the conduction system below the bifurcation of the His bundle. The early beat interrupts the expected sequence of the dominant rhythm and may be followed by a pause, by a normally conducted sinus impulse, or by a more complex interaction between the two rhythms. Identifying a PVC describes an electrical event but does not, by itself, define prognosis: apparently similar premature beats may be an incidental finding in a healthy heart, the expression of heart disease, or ectopic activity frequent enough to contribute to ventricular dysfunction.

Their detection becomes more frequent with increasing age, the presence of cardiovascular disease, and the duration of electrocardiographic recording. A tracing lasting a few seconds and prolonged monitoring therefore sample different phenomena; failure to document PVCs on the former does not exclude intermittent activity, whereas identifying a few beats on the latter does not necessarily imply disease. Clinical assessment integrates morphology, PVC burden, the relationship with symptoms, and the characteristics of the heart in which the arrhythmia occurs.

The specific issue addressed in this monograph is determining when PVCs require only diagnostic assessment and when they become a therapeutic target. Sequences of at least three rapid ventricular beats also fall within the spectrum of non-sustained ventricular tachycardia, which introduces additional questions related to the duration and organization of runs. In an individual patient these manifestations may coexist, but they should neither be confused nor pooled into a generic category of dangerous arrhythmia.

Electrophysiological origin and characteristics of the premature beat

A PVC may be generated by triggered activity, increased automaticity, or a reentrant circuit. Delayed afterdepolarizations, favored by intracellular calcium overload and adrenergic stimulation, are particularly relevant in some idiopathic forms. Early afterdepolarizations instead occur in settings of prolonged repolarization and may trigger polymorphic arrhythmias. In diseased tissue, heterogeneity of conduction and refractoriness can support different mechanisms, sometimes simultaneously. The appearance of an isolated beat alone does not allow its cellular mechanism to be assigned with certainty.

On ECG, a PVC usually appears as a premature, wide QRS complex with morphology different from that of the conducted beat, accompanied by secondary repolarization abnormalities. Duration, however, is not an absolute criterion: an origin close to the His-Purkinje system may generate relatively narrow complexes. The absence of a sinus P wave causally related to the QRS and analysis of the atrioventricular sequence help distinguish ventricular ectopy from a premature atrial contraction conducted with aberrancy. A retrograde P wave after the QRS is compatible with ventricular origin and does not convert the beat into a supraventricular depolarization.

A complete compensatory pause occurs when the PVC does not alter sinus-node timing and the subsequent sinus impulse encounters suitable conduction conditions. It is not constant: ventriculoatrial conduction may reset the sinus node, whereas an interpolated beat is inserted between two sinus depolarizations without an obvious pause. Interpolation can nevertheless modify atrioventricular conduction of the following beat through concealed retrograde penetration of the AV node. For these reasons, pause regularity must be interpreted together with P waves and intervals, avoiding rigid equivalences between the pause and the site of origin.

The coupling, that is, the interval between the preceding beat and the PVC, may be relatively fixed or variable. Marked variability suggests several possibilities, including parasystole, but diagnosing a protected ectopic focus requires overall temporal consistency and cannot be based on two different intervals. Fusion beats result from simultaneous activation of portions of the ventricles by the sinus impulse and the ectopic impulse: they produce an intermediate QRS and may make activity arising from a single focus appear multiform.

The terms bigeminy and trigeminy describe the repetitive relationship between conducted beats and PVCs; a couplet consists of two consecutive ventricular beats. These descriptions are useful for reconstructing arrhythmia organization but are not independent prognostic scales. Persistent bigeminy may produce a very high burden even without runs, whereas a few couplets in scar-related heart disease may carry a different meaning. Historical classifications based only on frequency and complexity do not replace assessment of the underlying substrate.

Monomorphic forms often suggest a dominant origin, but a single morphology may also represent the predominant exit of a broader substrate. Multiple morphologies may indicate distinct foci, different exits from the same focus, variations in conduction, or fusion. Artifacts and electrode displacement must also be excluded before diagnosing multifocal ventricular ectopy. This distinction is particularly important when it guides cardiac magnetic resonance or the ablation strategy.

The R-on-T phenomenon describes a premature beat falling during the preceding repolarization. Its significance depends on the actual coupling interval, dispersion of refractoriness, and the clinical context. Not every graphic overlap with the T wave heralds ventricular fibrillation; conversely, in selected patients a very early PVC, often arising from the Purkinje system, may act as a reproducible trigger of a malignant arrhythmia. This possibility requires dedicated assessment and should not be indiscriminately extrapolated to common ventricular ectopy.

Sites of origin, substrates, and clinical manifestations

Idiopathic PVCs frequently arise from the outflow tracts, but they may also originate from the fascicles, papillary muscles, valvular annuli, or other ventricular regions. The term idiopathic assumes that an evaluation proportionate to the presentation has not identified structural heart disease or a recognizable arrhythmic syndrome. A normal initial echocardiogram is reassuring but does not always complete that evaluation, especially when the ECG, family history, symptoms, or behavior during exercise suggest disease not evident on echocardiography.

A left bundle branch block morphology with an inferior axis often points toward an origin in the right ventricular outflow tract; nearby origins in the left ventricle or aortic cusps may, however, produce similar configurations. Precordial transition, polarity in the limb leads, and comparison with the sinus QRS help narrow the anatomical hypothesis. A right bundle branch block morphology frequently suggests a left ventricular origin without providing definitive localization. Electrocardiographic algorithms prepare the reasoning and mapping strategy but are influenced by individual anatomy and electrode placement.

PVCs associated with heart disease may occur in the setting of ischemic scar, dilated, hypertrophic, or arrhythmogenic cardiomyopathies, valvular disease, and inflammatory or infiltrative processes. In these settings the premature beat may be a marker of the underlying abnormality and, in some circumstances, the trigger for a reentrant circuit. The relationship is not unidirectional, however: heart disease promotes ectopy, and persistent ectopic burden may worsen already impaired ventricular function. Determining which component predominates is often one of the goals of the diagnostic workup.

Modulating factors include potassium and magnesium abnormalities, hypoxemia, endocrine disorders, proarrhythmic drugs, and sympathomimetic substances. Insufficient sleep, stress, alcohol, and stimulants may increase the perception or frequency of beats in individual patients, but they should not automatically be treated as the sole cause of the arrhythmia. The relationship with caffeine or daily activities is variable: a change in habits becomes meaningful when it produces a reproducible change, without replacing assessment for underlying heart disease.

The typical symptom is the sensation of a skipped beat followed by a stronger beat. Patients often perceive mainly the subsequent contraction, supported by greater filling and postextrasystolic potentiation. Others report irregularity, pulsations in the neck, chest discomfort, or a brief hollow sensation. Symptom intensity correlates poorly with burden: a few PVCs may be very disturbing, whereas nearly continuous activity may be discovered incidentally.

A PVC may produce reduced stroke volume and a poorly palpable peripheral pulse. During bigeminy this sometimes causes a pulse deficit, with a palpated rate or a rate detected by an optical device lower than the electrical rate. Apparent bradycardia should therefore be verified by ECG before being attributed to sinus-node disease or atrioventricular block. This discrepancy may also explain some alerts generated by wearable devices.

Syncope, progressive dyspnea, reduced exercise tolerance, or chest pain require interpretation beyond the mere presence of PVCs. Recording premature beats away from the episode does not demonstrate that they caused loss of consciousness. Tachyarrhythmias, bradyarrhythmias, hemodynamic conditions, and acute disease should be investigated. Likewise, a family history of sudden death or cardiomyopathy lowers the threshold for further assessment even when the patient reports only palpitations.

Diagnostic pathway and measurement of PVC burden

The twelve-lead ECG documents both ectopy and the baseline rhythm. During sinus rhythm it should be examined for signs of previous infarction, conduction disorders, repolarization abnormalities, and other findings that may suggest heart disease or an electrical syndrome. When the PVC is not recorded during the visit, a previous complete tracing may be more informative than a report listing only the number of events. A single-lead signal may confirm an irregularity but offers limited ability to localize the origin or establish a differential diagnosis.

Ambulatory monitoring quantifies ectopic activity and links symptoms to rhythm. The PVC burden is generally expressed as the percentage of premature ventricular complexes among all analyzed beats; the report should make clear how artifacts, excluded segments, and runs were handled. The absolute daily number and the percentage provide complementary information because the average underlying heart rate changes the denominator. A percentage must always be interpreted in relation to the duration and quality of the recording.

Variability between hours and days may be substantial. A single twenty-four-hour recording may underestimate or overestimate usual exposure, especially when the measured value is close to a threshold that would change clinical management. Longer monitoring or a repeat recording is reasonable when this uncertainty needs to be clarified, when sporadic symptoms need evaluation, or when treatment response must be measured. Duration should be selected according to the clinical question, without assuming that a longer device is always necessary.

Analysis should distinguish the number of morphologies, circadian distribution, couplets and runs, behavior in relation to sinus rate, and correspondence with the symptom diary. Automated counts require review of representative tracings because supraventricular aberrancy, noise, and double counting of the T wave can alter the result. Comparisons between recordings are more reliable when technique and clinical conditions are sufficiently comparable. A percentage change alone, without accounting for spontaneous fluctuation, may overestimate the effectiveness of an intervention.

Echocardiography assesses ventricular size and function, regional abnormalities, valvular structures, and other clues to heart disease. In the presence of frequent ectopy, selection of beats for measurement of volumes and ejection fraction is critical: premature beats and immediately postextrasystolic beats have different loading and contractile conditions. Representative sequences should be used, and an estimate obtained during persistent bigeminy should be interpreted cautiously. Technical data quality must be considered before diagnosing or excluding dysfunction.

Cardiac magnetic resonance becomes important when the presentation is atypical for an idiopathic form, the echocardiogram is equivocal, or there is dysfunction, suspicious morphology, baseline ECG abnormalities, or a significant family history. Assessment for fibrosis and tissue characteristics may reveal a substrate not detectable by echocardiography and may change prognosis and the therapeutic strategy. It is not necessary in every person with rare PVCs and an otherwise reassuring evaluation; its usefulness depends on the likelihood of finding information that would change management.

Exercise testing clarifies the behavior of ectopy during exercise and recovery, its relationship with symptoms, and any suspicion of ischemia. Suppression as heart rate increases may occur in idiopathic forms but does not certify benignity. An increase, the appearance of multiple morphologies, or polymorphic arrhythmias requires greater attention, especially when associated with syncope or a relevant family history. PVCs during recovery also have prognostic associations in selected populations, but by themselves they do not establish a diagnosis or an indication for a procedure.

Blood tests and coronary evaluation should address specific clinical hypotheses. Electrolytes, renal function, and thyroid function are useful when the history or therapies suggest correctable abnormalities; biomarkers of myocardial injury belong to the pathway for suspected acute events. Genetic testing is not a routine investigation for isolated PVCs: it becomes relevant when the phenotype or family history suggests a cardiomyopathy or channelopathy, within a specialist assessment that includes interpretation and counseling.

Ectopic burden and cardiomyopathy induced or aggravated by PVCs

PVC-induced cardiomyopathy is ventricular dysfunction substantially attributable to persistent exposure to ectopy. Mechanisms include activation dyssynchrony, mechanical inefficiency, alterations in filling, and cellular remodeling. It does not necessarily require a very high average heart rate, as in classic tachycardia-induced cardiomyopathy: repeated premature and discoordinated ventricular contractions may be sufficient. In an already diseased heart, it is often more accurate to speak of dysfunction aggravated by PVCs.

A burden around 10% is commonly used as a level at which this mechanism should be considered in the presence of reduced ventricular function; burdens above 20% are associated with a higher risk. These values are not universal biological boundaries. Some patients tolerate a high burden for a long time without dysfunction, whereas a causal contribution may be plausible at lower percentages, particularly if the recording underestimates actual exposure or a vulnerable substrate coexists. The threshold guides reasoning but does not establish causality.

Susceptibility also depends on duration of exposure and activation characteristics. A very wide ectopic QRS, certain epicardial origins, and interpolation have been associated with a higher probability of dysfunction in different series. These features may reflect more pronounced dyssynchrony but do not form an algorithm capable of predicting the course of an individual patient with certainty. The absence of symptoms does not protect against cardiomyopathy and may simply delay recognition of a high burden.

Diagnosis requires examining both directions of the relationship between ectopy and dysfunction. A primary cardiomyopathy may generate frequent PVCs, whereas an idiopathic focus may progressively cause dilation and impaired function. A dominant morphology, a consistent burden, and the absence of an alternative cause strengthen the arrhythmic hypothesis; fibrosis on cardiac magnetic resonance, familial abnormalities, or a specific structural phenotype require consideration of concomitant disease. The presence of scar does not, however, exclude the possibility that reducing ectopy may improve residual function.

Recovery after suppression of the arrhythmia is among the most convincing pieces of evidence for a causal contribution, but it is observed retrospectively. Before treatment, the diagnosis often remains probabilistic. Improvement generally occurs over months, and its magnitude varies with the duration of dysfunction, the underlying substrate, and the completeness of ectopic reduction. Assessment performed too early may fail to detect it; incomplete recovery requires verification of residual burden and reassessment for other causes, rather than automatically being interpreted as treatment failure.

With preserved function and a high burden, the central issue is surveillance for the development of remodeling and discussion of options according to symptoms, site of origin, and patient preferences. It has not been demonstrated that systematically eliminating all asymptomatic PVCs improves survival. When reduced function plausibly related to ectopy develops, the objective changes: suppression of the focus may become an intervention aimed at ventricular recovery, together with treatment of heart failure when indicated.

Drug therapy and ablation of the ectopic focus

Therapeutic selection distinguishes three objectives: relieving documented symptoms, correcting dysfunction induced or aggravated by ectopy, and managing PVCs that trigger dangerous arrhythmias. In patients with limited ectopic activity, a reassuring evaluation, and tolerable symptoms, explanation of the finding and an appropriately proportioned follow-up may be sufficient. Reassurance should result from the assessment rather than from an assumption that every PVC is harmless. Likewise, the mere presence of premature beats does not justify continuous antiarrhythmic therapy.

Correction of reversible factors includes reviewing drugs and substances and treating documented electrolyte abnormalities and conditions that increase myocardial vulnerability. Indiscriminate supplementation in the absence of a deficiency is not useful, nor should every fluctuation be attributed to a single food. When the arrhythmia occurs in ischemic or inflammatory heart disease or in heart failure, treating the underlying disease changes the context in which ectopy arises. Reduction of the PVC count, although desirable in some situations, does not replace interventions with proven prognostic benefit for the underlying heart disease.

Beta-blockers may reduce symptoms and ectopy, especially when there is an adrenergic component or another cardiovascular indication. Their suppressive effect is variable and must be balanced against bradycardia, hypotension, fatigue, and tolerability. In selected patients with preserved ventricular function and idiopathic PVCs, verapamil or diltiazem are possible alternatives. Non-dihydropyridine calcium-channel blockers are not a generic choice in significant systolic dysfunction because of their negative inotropic effect, nor should they automatically be carried over to the management of an undiagnosed wide-QRS tachycardia.

Class Ic drugs may be considered in selected settings after adequate exclusion of relevant ischemic or structural heart disease and other contraindications. Effective suppression of ectopy does not equate to prognostic safety: experience with these drugs in ischemic heart disease requires careful patient selection. Monitoring includes ECG, conduction, organ function, and drug interactions according to the specific agent. Amiodarone and other antiarrhythmics with proarrhythmic potential or systemic toxicity are not a routine response to symptomatic PVCs in an otherwise normal heart.

Catheter ablation is a major option for symptomatic idiopathic PVCs arising from the right ventricular outflow tract or left fascicles and for cardiomyopathy attributed to predominantly monomorphic activity. For other sites, the balance between efficacy, difficulty, and risk changes the sequence between drugs and the procedure. The decision considers documentation of the focus, clinical impact, the likelihood of achieving adequate mapping, and patient preferences. It does not necessarily require a long sequence of ineffective drugs when the indication for ablation is already well established.

Mapping seeks the site of earliest activation relative to the surface QRS and, when useful, integrates comparison between the spontaneous QRS and that obtained by pacing. Good pace mapping is supportive but does not by itself prove that the catheter is at the true origin, particularly in areas with preferential conduction or multiple exits. A scarcity of PVCs during the procedure, sometimes influenced by sedation and spontaneous variability, may limit mapping and requires an individualized strategy.

Anatomical location determines procedural risks. Para-Hisian regions require particular attention to the conduction system; the aortic cusps, left ventricular summit, and some epicardial sites require consideration of coronary proximity. Papillary muscles may present catheter-stability difficulties and multiple activation exits, with recurrence of different morphologies. Vascular access, possible entry into the left heart, and the need for complex approaches add specific risks. Success rates for an easily accessible focus cannot be applied to every location.

In asymptomatic patients with preserved function and a persistently very high burden, ablation may be discussed in selected cases, but the prognostic benefit of preventive suppression has not been established. Spontaneous burden variability and the feasibility of functional follow-up enter the balance. An implantable cardioverter-defibrillator is not indicated simply on the basis of PVC count: any indication derives from the underlying heart disease and overall arrhythmic risk, or from previous malignant events according to the relevant pathway.

A distinct situation is that of PVCs that repeatedly trigger ventricular fibrillation or episodes of electrical storm. In experienced centers, mapping and ablation of the trigger may help control recurrences, together with treatment of the substrate and other necessary measures. Successful elimination of the trigger does not automatically demonstrate disappearance of residual risk and, by itself, does not justify foregoing defibrillator protection when it remains indicated.

Prognosis, reassessment, and special situations

The prognosis of PVCs is favorable in many patients in whom an appropriate evaluation identifies no heart disease, dysfunction, or suspicious features. The conclusion must nevertheless remain tied to the documented clinical picture: a normal evaluation today does not make new symptoms or changes in the arrhythmia irrelevant. In structural heart disease, ectopy should be interpreted together with ventricular function, scar, clinical evolution, and other arrhythmias, avoiding attribution to the number of beats of a prognostic power that it does not possess in isolation.

Follow-up is determined by the probability of clinically relevant evolution. A high burden justifies surveillance of ventricular function and, when necessary, repeat quantification; a rare finding in the absence of suspicious elements may require a much less intensive pathway. There is no single interval appropriate for everyone. Increasing symptoms, declining functional capacity, presyncope or syncope, new ECG abnormalities, and changes in family history are reasons to bring reassessment forward.

After drug therapy or ablation, response should be measured against the original objective. In symptomatic patients, the relationship between perceived improvement and rhythm matters; in arrhythmia-induced cardiomyopathy, residual burden and recovery of function must also be assessed. Persistence of some PVCs does not equal failure, whereas disappearance of palpitations does not prove adequate suppression. A marked reduction in burden may be clinically effective even without absolute elimination of every premature beat.

Recurrence after ablation may result from recovery of conduction at the treated site, a different exit, or a new focus. Comparing tracings before and after the procedure helps distinguish these possibilities and guides any repeat intervention. If dysfunction recurs in a patient who had previously improved, repeat quantification of ectopy is particularly important. In the presence of concomitant cardiomyopathy, recovery of ejection fraction does not automatically justify discontinuation of therapies for the underlying disease.

In athletes, decisions about physical activity consider morphology, behavior during exercise, imaging, and personal and family history. The count alone does not distinguish harmless adaptation from a sign of heart disease. In children, interpretation requires age- and function-appropriate references, whereas in pregnancy physiological changes must be integrated with any symptoms or signs of new disease. In both settings, selection of drugs or procedures requires a specific risk-benefit balance rather than simple extrapolation from a nonpregnant adult.

Communication with the patient should distinguish subjective discomfort from risk and clarify that monitoring is used to answer clinical questions. Repeatedly checking the pulse or a wearable device may amplify perception without improving assessment, especially in the presence of pulse deficit and imprecise automated algorithms. A shared plan, with therapeutic goals and specific reasons to seek reassessment, allows PVCs to be managed without trivializing them and without turning every day-to-day variation into a sign of progression.